Myriad Genetics Submits Vivecon IND

Myriad Genetics has filed an investigational new drug application (IND) with the FDA to begin human clinical trials with Vivecon, a potential AIDS treatment.

Vivecon is a small-molecule drug candidate designed to inhibit viral maturation and is the first antiviral drug candidate Myriad has advanced to human clinical trials.

The first planned Phase I trial for Vivecon will assess the pharmacokinetics, absorption and tolerability of the compound. If the trial is successful, the company will begin a Phase IIa multiple ascending-dose trial, Myriad said.